Veracyte has announced a multi-year partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development of new cancer therapies.
They will combine their abilities to offer new insights into the biology of metastatic tumours, helping to develop new cancer treatments.
The collaboration will utilise Gustave Roussy's extensive collection of tumour samples and related data, along with Veracyte's Biopharma Atlas, a machine learning-powered, multi-omic solution aimed at enhancing the effectiveness and efficacy of clinical studies.
Gustave Roussy’s department of therapeutic innovation and early clinical trials will deliver metastatic tumour samples and information for several cancer indications. These are derived from research projects, specifically for new immunotherapies.
Veracyte intends to combine these resources with its multi-omics testing and machine learning capabilities, resulting in the development of a Veracyte Biopharma Atlas reference database for genomic and immunomic biomarkers.
Using the comprehensive understanding of each tumour's biology, especially its immune context, the company will extract additional insights regarding which tumours are more likely to be responsive to a specific therapy.
Veracyte’s Biopharma business unit general manager Corinne Danan said: “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients' tumour samples and data from innovative cancer therapies.
“Ultimately, we believe this tool may help our biopharmaceutical partners accelerate the development of new, precision-medicine therapies that improve outcomes for patients with cancer.”
